dc.contributor.author | Wang, H. | |
dc.contributor.author | Hatzixanthis, K. | |
dc.contributor.author | Barnard, A. | |
dc.contributor.author | Shah, R. | |
dc.contributor.author | Saveri, E. | |
dc.contributor.author | Pitts, K. | |
dc.contributor.author | Piwowarczyk, D. | |
dc.contributor.author | Patil, G. | |
dc.contributor.author | Baines, Simon D. | |
dc.contributor.author | Wilkinson, A. | |
dc.contributor.author | Fairhead, H. | |
dc.date.accessioned | 2014-11-12T10:44:27Z | |
dc.date.available | 2014-11-12T10:44:27Z | |
dc.date.issued | 2011-09 | |
dc.identifier.citation | Wang , H , Hatzixanthis , K , Barnard , A , Shah , R , Saveri , E , Pitts , K , Piwowarczyk , D , Patil , G , Baines , S D , Wilkinson , A & Fairhead , H 2011 , ' SASP: targeted delivery to Gram-negative pathogens ' , 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC) , Chicago , United States , 17/09/11 - 20/09/11 . | |
dc.identifier.citation | conference | |
dc.identifier.uri | http://hdl.handle.net/2299/14739 | |
dc.description.abstract | Background: Gram-negative bacteria are responsible for significant morbidity and mortality worldwide. Multi-drug resistance emergence has rendered many therapies ineffective. New therapies are urgently required to widen treatment options. SASPject technology delivers small acid-soluble spore protein (SASP) genes to target bacteria using modified bacteriophage vectors, resulting in rapid killing. SASP is a unique antibacterial protein that non-specifically binds bacterial DNA and halts DNA replication and gene expression. In this study we present the first data for a Gram-negative targeted SASPject vector (PT3.1) which shows in vitro activity against Escherichia coli (EC) and Pseudomonas aeruginosa (PA). Methods: We evaluated efficacy of SASPject PT3.1 vs. EC (N=5) & PA (N=5) using a microtitre tray fixed duration (3 h) kill method. Log-phase cultures (1x105 cfu/mL) were prepared in supplemented (MgSO4 & CaCl2, 5 mM; glucose, 0.1% w/v) LB broth (LBC) & exposed to 2x108 plaque forming units (pfu)/mL of PT3.1. PT3.1 antimicrobial activity was determined using agar-based culture following incubation (37oC). Additionally, rate of PT3.1 kill was determined using a kill-curve technique; a selection of EC & PA strains from the fixed duration kill study were evaluated & bacterial viable counts determined over 3 h on LBC agar. Results: SASPject PT3.1 elicited good antimicrobial activity vs. EC & PA evaluated in this study; the median reduction in viable counts for PT3.1-treated cultures in the fixed 3 h kill was 99.1%. Kill curve data suggested rapid EC & PA killing; viable counts (log10 cfu/mL range) of PT3.1-treated cultures were 2.36->4.01, 3.04-4.06, and 3.40-4.16 lower than corresponding controls after 1, 2, and 3 h respectively. Conclusions: 1. SASPject PT3.1 demonstrated good antimicrobial activity vs. EC & PA evaluated in this study in a fixed 3 h exposure period 2. PT3.1 was bactericidal (≥3 log10 cfu/mL decline) vs. 3 of 4 isolates (1EC & 2PA) evaluated in time-kill curves after 1 h and against all isolates after 2 h 3. Further evaluations of Gram-negative SASPject phage are warranted | en |
dc.language.iso | eng | |
dc.title | SASP: targeted delivery to Gram-negative pathogens | en |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Microbiology and Biotechnology | |
dc.contributor.institution | Biosciences Research Group | |
dc.contributor.institution | Centre for Research in Mechanisms of Disease and Drug Discovery | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Centre for Future Societies Research | |
dc.description.status | Non peer reviewed | |
rioxxterms.type | Other | |
herts.preservation.rarelyaccessed | true | |